|
G |
Chrna7 |
cholinergic receptor nicotinic alpha 7 subunit |
multiple interactions |
ISO |
beta-thujone inhibits the reaction [Acetylcholine results in increased activity of CHRNA7 protein]; beta-thujone inhibits the reaction [Choline results in increased activity of CHRNA7 protein] |
CTD |
PMID:28395994 |
|
NCBI chr 1:116,711,559...116,837,269
Ensembl chr 1:116,714,711...116,837,240
|
|
G |
Gabra1 |
gamma-aminobutyric acid type A receptor subunit alpha 1 |
multiple interactions |
ISO |
beta-thujone inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]] |
CTD |
PMID:15588619 |
|
NCBI chr10:26,595,151...26,650,611
Ensembl chr10:26,595,160...26,650,864
|
|
G |
Gabrb2 |
gamma-aminobutyric acid type A receptor subunit beta 2 |
multiple interactions |
ISO |
beta-thujone inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]] |
CTD |
PMID:15588619 |
|
NCBI chr10:26,936,592...27,156,141
Ensembl chr10:26,936,551...27,151,251
|
|
G |
Gabrg2 |
gamma-aminobutyric acid type A receptor subunit gamma 2 |
multiple interactions |
ISO |
beta-thujone inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]] |
CTD |
PMID:15588619 |
|
NCBI chr10:26,374,693...26,463,937
Ensembl chr10:26,374,694...26,464,346
|
|
|
G |
Col1a2 |
collagen type I alpha 2 chain |
affects expression |
ISO |
Camphor analog affects the expression of COL1A2 mRNA |
CTD |
PMID:24704097 |
|
NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
decreases activity |
EXP |
Camphor results in decreased activity of CYP2B1 protein |
CTD |
PMID:9242356 |
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions |
ISO |
Camphor inhibits the reaction [CYP2B6 protein results in increased hydrolysis of Bupropion] |
CTD |
PMID:18611395 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
Camphor binds to and results in increased activity of ESR1 protein |
CTD |
PMID:27633901 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Gabra1 |
gamma-aminobutyric acid type A receptor subunit alpha 1 |
multiple interactions |
ISO |
Camphor promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]] |
CTD |
PMID:15588619 |
|
NCBI chr10:26,595,151...26,650,611
Ensembl chr10:26,595,160...26,650,864
|
|
G |
Gabrb2 |
gamma-aminobutyric acid type A receptor subunit beta 2 |
multiple interactions |
ISO |
Camphor promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]] |
CTD |
PMID:15588619 |
|
NCBI chr10:26,936,592...27,156,141
Ensembl chr10:26,936,551...27,151,251
|
|
G |
Gabrg2 |
gamma-aminobutyric acid type A receptor subunit gamma 2 |
multiple interactions |
ISO |
Camphor promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]] |
CTD |
PMID:15588619 |
|
NCBI chr10:26,374,693...26,463,937
Ensembl chr10:26,374,694...26,464,346
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
Camphor inhibits the reaction [cinnamaldehyde results in increased activity of MPO protein] |
CTD |
PMID:21466812 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Pgr |
progesterone receptor |
multiple interactions |
ISO |
Camphor binds to and results in decreased activity of PGR protein |
CTD |
PMID:27633901 |
|
NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
affects expression |
ISO |
Camphor analog affects the expression of RUNX2 mRNA |
CTD |
PMID:24704097 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Sparc |
secreted protein acidic and cysteine rich |
affects expression |
ISO |
Camphor analog affects the expression of SPARC mRNA |
CTD |
PMID:24704097 |
|
NCBI chr10:39,516,394...39,538,252
Ensembl chr10:39,516,406...39,538,396
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions |
EXP |
Lidocaine promotes the reaction [Camphor results in increased activity of TRPV1 protein] |
CTD |
PMID:18172555 |
|
NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513
|
|
G |
Trpv3 |
transient receptor potential cation channel, subfamily V, member 3 |
increases activity multiple interactions |
ISO |
Camphor results in increased activity of TRPV3 protein isopentenyl pyrophosphate inhibits the reaction [Camphor results in increased activity of TRPV3 protein] |
CTD |
PMID:21353389 |
|
NCBI chr10:57,883,546...57,915,865
Ensembl chr10:57,883,546...57,913,296
|
|
|
G |
Casp3 |
caspase 3 |
increases activity |
ISO |
28-deoxonimbolide results in increased activity of CASP3 protein |
CTD |
PMID:21381696 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
increases activity |
ISO |
28-deoxonimbolide results in increased activity of CASP8 protein |
CTD |
PMID:21381696 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases activity |
ISO |
28-deoxonimbolide results in increased activity of CASP9 protein |
CTD |
PMID:21381696 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
|
G |
Casp3 |
caspase 3 |
increases activity |
ISO |
azadiradione results in increased activity of CASP3 protein |
CTD |
PMID:21381696 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
increases activity |
ISO |
azadiradione results in increased activity of CASP8 protein |
CTD |
PMID:21381696 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases activity |
ISO |
azadiradione results in increased activity of CASP9 protein |
CTD |
PMID:21381696 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
increases expression |
ISO |
azadiradione results in increased expression of HSPA1A mRNA |
CTD |
PMID:30309986 |
|
NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227
|
|
|
G |
Calml5 |
calmodulin-like 5 |
increases expression |
ISO |
beta-damascenone results in increased expression of CALM4 mRNA |
CTD |
PMID:22982537 |
|
NCBI chr17:66,394,433...66,395,352
|
|
G |
Casp14 |
caspase 14 |
increases expression affects localization |
ISO |
beta-damascenone results in increased expression of CASP14 mRNA beta-damascenone affects the localization of CASP14 protein |
CTD |
PMID:22982537 |
|
NCBI chr 7:10,929,759...10,932,591
Ensembl chr 7:10,926,725...10,933,405
|
|
G |
Ces3a |
carboxylesterase 3a |
increases expression |
ISO |
beta-damascenone results in increased expression of CES3 mRNA |
CTD |
PMID:22982537 |
|
NCBI chr19:32,992,386...33,000,562
|
|
G |
Clca1 |
chloride channel accessory 1 |
increases expression |
ISO |
beta-damascenone results in increased expression of CLCA1 mRNA |
CTD |
PMID:22982537 |
|
NCBI chr 2:233,938,677...233,964,369
Ensembl chr 2:233,938,677...233,964,369
|
|
G |
Clca2 |
chloride channel accessory 2 |
increases expression |
ISO |
beta-damascenone results in increased expression of CLCA2 mRNA |
CTD |
PMID:22982537 |
|
NCBI chr 2:233,993,619...234,022,691
Ensembl chr 2:233,995,078...234,022,199
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
increases expression |
ISO |
beta-damascenone results in increased expression of CYP17A1 mRNA |
CTD |
PMID:22982537 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Fcgbp |
Fc gamma binding protein |
increases expression |
ISO |
beta-damascenone results in increased expression of FCGBP mRNA |
CTD |
PMID:22982537 |
|
NCBI chr 1:83,374,979...83,413,082
Ensembl chr 1:83,372,127...83,413,083
|
|
G |
Flg |
filaggrin |
increases expression |
ISO |
beta-damascenone results in increased expression of FLG mRNA; beta-damascenone results in increased expression of FLG protein |
CTD |
PMID:22982537 |
|
NCBI chr 2:178,884,793...178,912,986
|
|
G |
Hrnr |
hornerin |
increases expression |
ISO |
beta-damascenone results in increased expression of HRNR mRNA |
CTD |
PMID:22982537 |
|
|
|
G |
Il20ra |
interleukin 20 receptor subunit alpha |
increases expression |
ISO |
beta-damascenone results in increased expression of IL20RA mRNA |
CTD |
PMID:22982537 |
|
NCBI chr 1:14,424,215...14,494,226
Ensembl chr 1:14,451,228...14,493,602
|
|
G |
Il36rn |
interleukin 36 receptor antagonist |
increases expression |
ISO |
beta-damascenone results in increased expression of IL36RN mRNA |
CTD |
PMID:22982537 |
|
NCBI chr 3:7,044,419...7,051,016
Ensembl chr 3:7,044,406...7,051,016
|
|
G |
Krt1 |
keratin 1 |
increases expression |
ISO |
beta-damascenone results in increased expression of KRT1 mRNA |
CTD |
PMID:22982537 |
|
NCBI chr 7:132,976,618...132,981,844
Ensembl chr 7:132,976,620...132,981,844
|
|
G |
Krt10 |
keratin 10 |
increases expression |
ISO |
beta-damascenone results in increased expression of KRT10 mRNA |
CTD |
PMID:22982537 |
|
NCBI chr10:84,338,695...84,343,279
Ensembl chr10:84,338,706...84,343,701
|
|
G |
Lce1b |
late cornified envelope 1B |
increases expression |
ISO |
beta-damascenone results in increased expression of LCE1B mRNA |
CTD |
PMID:22982537 |
|
NCBI chr 2:178,255,351...178,257,533
Ensembl chr 2:178,256,213...178,257,985
|
|
G |
Lce1d |
late cornified envelope 1D |
increases expression |
ISO |
beta-damascenone results in increased expression of LCE1D mRNA |
CTD |
PMID:22982537 |
|
|
|
G |
Lce1f |
late cornified envelope 1F |
increases expression |
ISO |
beta-damascenone results in increased expression of LCE1F mRNA |
CTD |
PMID:22982537 |
|
NCBI chr 2:178,305,786...178,307,372
Ensembl chr 2:178,305,786...178,307,372
|
|
G |
Lipm |
lipase, family member M |
increases expression |
ISO |
beta-damascenone results in increased expression of LIPM mRNA |
CTD |
PMID:22982537 |
|
NCBI chr 1:231,618,145...231,637,599
Ensembl chr 1:231,618,284...231,637,410
|
|
G |
Loricrin |
loricrin cornified envelope precursor protein |
increases expression |
ISO |
beta-damascenone results in increased expression of LORICRIN mRNA |
CTD |
PMID:22982537 |
|
NCBI chr 2:177,558,062...177,560,960
Ensembl chr 2:177,558,252...177,559,807
|
|
G |
Otop3 |
otopetrin 3 |
increases expression |
ISO |
beta-damascenone results in increased expression of OTOP3 mRNA |
CTD |
PMID:22982537 |
|
NCBI chr10:100,577,346...100,588,729
Ensembl chr10:100,577,392...100,588,726
|
|
G |
Pla2g4f |
phospholipase A2, group IVF |
increases expression |
ISO |
beta-damascenone results in increased expression of PLA2G4F mRNA |
CTD |
PMID:22982537 |
|
NCBI chr 3:107,249,053...107,266,201
Ensembl chr 3:107,250,075...107,264,689
|
|
G |
Plcxd1 |
phosphatidylinositol-specific phospholipase C, X domain containing 1 |
increases expression |
ISO |
beta-damascenone results in increased expression of PLCXD1 mRNA |
CTD |
PMID:22982537 |
|
NCBI chr12:46,578,917...46,582,181
Ensembl chr12:46,579,225...46,582,392
|
|
G |
Sdr16c5 |
short chain dehydrogenase/reductase family 16C, member 5 |
increases expression |
ISO |
beta-damascenone results in increased expression of SDR16C5 mRNA |
CTD |
PMID:22982537 |
|
NCBI chr 5:17,018,813...17,043,974
Ensembl chr 5:17,018,813...17,040,970
|
|
G |
Susd2 |
sushi domain containing 2 |
increases expression |
ISO |
beta-damascenone results in increased expression of SUSD2 mRNA |
CTD |
PMID:22982537 |
|
NCBI chr20:13,017,516...13,024,820
Ensembl chr20:13,017,477...13,024,903
|
|
G |
Tmprss4 |
transmembrane serine protease 4 |
increases expression |
ISO |
beta-damascenone results in increased expression of TMPRSS4 mRNA |
CTD |
PMID:22982537 |
|
NCBI chr 8:45,475,819...45,508,409
Ensembl chr 8:45,476,053...45,508,409
|
|
|
G |
Col1a2 |
collagen type I alpha 2 chain |
affects expression |
ISO |
Camphor analog affects the expression of COL1A2 mRNA |
CTD |
PMID:24704097 |
|
NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
decreases activity |
EXP |
Camphor results in decreased activity of CYP2B1 protein |
CTD |
PMID:9242356 |
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions |
ISO |
Camphor inhibits the reaction [CYP2B6 protein results in increased hydrolysis of Bupropion] |
CTD |
PMID:18611395 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
Camphor binds to and results in increased activity of ESR1 protein |
CTD |
PMID:27633901 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Gabra1 |
gamma-aminobutyric acid type A receptor subunit alpha 1 |
multiple interactions |
ISO |
Camphor promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]] |
CTD |
PMID:15588619 |
|
NCBI chr10:26,595,151...26,650,611
Ensembl chr10:26,595,160...26,650,864
|
|
G |
Gabrb2 |
gamma-aminobutyric acid type A receptor subunit beta 2 |
multiple interactions |
ISO |
Camphor promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]] |
CTD |
PMID:15588619 |
|
NCBI chr10:26,936,592...27,156,141
Ensembl chr10:26,936,551...27,151,251
|
|
G |
Gabrg2 |
gamma-aminobutyric acid type A receptor subunit gamma 2 |
multiple interactions |
ISO |
Camphor promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]] |
CTD |
PMID:15588619 |
|
NCBI chr10:26,374,693...26,463,937
Ensembl chr10:26,374,694...26,464,346
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
Camphor inhibits the reaction [cinnamaldehyde results in increased activity of MPO protein] |
CTD |
PMID:21466812 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Pgr |
progesterone receptor |
multiple interactions |
ISO |
Camphor binds to and results in decreased activity of PGR protein |
CTD |
PMID:27633901 |
|
NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
affects expression |
ISO |
Camphor analog affects the expression of RUNX2 mRNA |
CTD |
PMID:24704097 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Sparc |
secreted protein acidic and cysteine rich |
affects expression |
ISO |
Camphor analog affects the expression of SPARC mRNA |
CTD |
PMID:24704097 |
|
NCBI chr10:39,516,394...39,538,252
Ensembl chr10:39,516,406...39,538,396
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions |
EXP |
Lidocaine promotes the reaction [Camphor results in increased activity of TRPV1 protein] |
CTD |
PMID:18172555 |
|
NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513
|
|
G |
Trpv3 |
transient receptor potential cation channel, subfamily V, member 3 |
increases activity multiple interactions |
ISO |
Camphor results in increased activity of TRPV3 protein isopentenyl pyrophosphate inhibits the reaction [Camphor results in increased activity of TRPV3 protein] |
CTD |
PMID:21353389 |
|
NCBI chr10:57,883,546...57,915,865
Ensembl chr10:57,883,546...57,913,296
|
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
multiple interactions |
ISO |
fenchone binds to and results in decreased activity of NR3C1 protein |
CTD |
PMID:27633901 |
|
NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
fenchone binds to and results in decreased activity of PPARG protein |
CTD |
PMID:27633901 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of ABCB11 mRNA] |
CTD |
PMID:28549656 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; [Glycyrrhetinic Acid affects the activity of ABCB1 protein] which affects the susceptibility to Vinblastine; [Glycyrrhetinic Acid affects the activity of ABCB1 protein] which results in increased abundance of Daunorubicin; Glycyrrhetinic Acid inhibits the reaction [ABCB1 protein results in increased uptake of Digoxin]; Glycyrrhetinic Acid inhibits the reaction [Verapamil results in increased activity of ABCB1 protein] |
CTD |
PMID:16904803 PMID:18204840 PMID:24380838 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of ABCB4 mRNA] |
CTD |
PMID:28549656 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions increases activity |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCC1 mRNA] Glycyrrhetinic Acid results in increased activity of ABCC1 protein [Glycyrrhetinic Acid affects the activity of ABCC1 protein] which affects the susceptibility to Doxorubicin; [Glycyrrhetinic Acid affects the activity of ABCC1 protein] which results in increased abundance of fluorexon |
CTD |
PMID:18204840 PMID:28549656 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
EXP |
Glycyrrhetinic Acid inhibits the reaction [ABCC2 protein results in increased transport of estradiol-17 beta-glucuronide] |
CTD |
PMID:18436619 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid affects the reaction [1-Naphthylisothiocyanate affects the expression of ABCC3 mRNA] |
CTD |
PMID:28549656 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
ISO |
Glycyrrhetinic Acid inhibits the reaction [ABCG2 protein results in increased transport of estradiol-17 beta-glucuronide] |
CTD |
PMID:18436619 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCG5 mRNA] |
CTD |
PMID:28549656 |
|
NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563
|
|
G |
Acat2 |
acetyl-CoA acetyltransferase 2 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid affects the reaction [1-Naphthylisothiocyanate affects the expression of ACAT2 mRNA] |
CTD |
PMID:28549656 |
|
NCBI chr 1:47,695,833...47,713,879
Ensembl chr 1:47,695,788...47,752,821
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
EXP |
18alpha-glycyrrhetinic acid inhibits the reaction [Monocrotaline results in increased expression of ACTA2 protein] |
CTD |
PMID:31325423 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Akr1c1 |
aldo-keto reductase family 1, member C1 |
decreases activity |
ISO |
Glycyrrhetinic Acid results in decreased activity of AKR1C1 protein |
CTD |
PMID:12604236 |
|
NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326
|
|
G |
Akr1c2 |
aldo-keto reductase family 1, member C2 |
decreases activity |
ISO |
Glycyrrhetinic Acid results in decreased activity of AKR1C2 protein |
CTD |
PMID:12604236 |
|
NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
affects activity decreases activity |
ISO |
18alpha-glycyrrhetinic acid affects the activity of AKR1C3 protein Glycyrrhetinic Acid results in decreased activity of AKR1C3 protein |
CTD |
PMID:11165023 PMID:12604236 |
|
NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
|
|
G |
Alb |
albumin |
multiple interactions |
ISO |
ALB protein binds to and affects the transport of Glycyrrhetinic Acid |
CTD |
PMID:8831264 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased activity of ALPL protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of ALPL mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [RUNX2 protein results in increased expression of ALPL mRNA] |
CTD |
PMID:21910061 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Atf6 |
activating transcription factor 6 |
multiple interactions |
EXP |
18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in increased expression of ATF6 mRNA] |
CTD |
PMID:35699857 |
|
NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
|
|
G |
Atp8b1 |
ATPase phospholipid transporting 8B1 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of ATP8B1 mRNA] |
CTD |
PMID:28549656 |
|
NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in increased expression of BAX]; 18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in increased expression of BAX protein] 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in decreased expression of BAX protein] |
CTD |
PMID:28414158 PMID:31325423 PMID:35699857 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in decreased expression of BCL2]; 18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in decreased expression of BCL2 protein] 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of BCL2 protein] |
CTD |
PMID:28414158 PMID:31325423 PMID:35699857 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased activity of BGLAP protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of BGLAP mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [RUNX2 protein results in increased expression of BGLAP mRNA] |
CTD |
PMID:21910061 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased activity of ALPL protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased activity of BGLAP protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased activity of RUNX2 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of ALPL mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of BGLAP mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of COL1A1 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of SP7 mRNA] |
CTD |
PMID:21910061 |
|
NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in increased expression of CASP3] |
CTD |
PMID:35699857 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
Glycyrrhetinic Acid inhibits the reaction [Carbon Tetrachloride results in decreased expression of CAT mRNA] |
CTD |
PMID:23341968 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in decreased expression of CDKN1B protein] |
CTD |
PMID:31325423 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of COL1A1 mRNA] |
CTD |
PMID:21910061 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions |
ISO |
Glycyrrhetinic Acid promotes the reaction [Hydrocortisone inhibits the reaction [IL1B protein results in increased secretion of CSF2 protein]] |
CTD |
PMID:10460758 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
EXP |
[brucine co-treated with Glycyrrhetinic Acid] results in decreased activity of CYP1A2 protein |
CTD |
PMID:21800547 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
EXP |
[brucine co-treated with Glycyrrhetinic Acid] results in decreased activity of CYP2E1 protein |
CTD |
PMID:21800547 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of CYP7A1 mRNA] |
CTD |
PMID:28549656 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions |
EXP |
18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in increased expression of EIF2AK3 mRNA] |
CTD |
PMID:35699857 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions |
ISO EXP |
18alpha-glycyrrhetinic acid inhibits the reaction [Cadmium Chloride results in increased expression of ERN1 protein] 18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in increased expression of ERN1 mRNA] |
CTD |
PMID:29444456 PMID:35699857 |
|
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
|
|
G |
Ggt1 |
gamma-glutamyltransferase 1 |
multiple interactions |
EXP |
18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in increased activity of GGT1 protein] |
CTD |
PMID:28414158 |
|
NCBI chr20:13,074,695...13,104,095
Ensembl chr20:13,074,700...13,108,442
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in increased activity of GPT protein] 18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased activity of GPT protein]; Glycyrrhetinic Acid inhibits the reaction [diosbulbin B results in increased activity of GPT protein] |
CTD |
PMID:28414158 PMID:28549656 PMID:36807597 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
multiple interactions |
ISO |
Glycyrrhetinic Acid inhibits the reaction [Carbon Tetrachloride results in decreased expression of GPX2 mRNA] |
CTD |
PMID:23341968 |
|
NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP |
18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in decreased expression of HMOX1 mRNA] |
CTD |
PMID:28414158 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
decreases expression |
ISO |
Glycyrrhetinic Acid results in decreased expression of HRAS protein |
CTD |
PMID:19958823 |
|
NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615
|
|
G |
Hsd11b1 |
hydroxysteroid 11-beta dehydrogenase 1 |
decreases activity |
ISO |
18alpha-glycyrrhetinic acid results in decreased activity of HSD11B1 protein |
CTD |
PMID:24135201 |
|
NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687
|
|
G |
Hsd11b2 |
hydroxysteroid 11-beta dehydrogenase 2 |
decreases activity multiple interactions |
ISO |
18alpha-glycyrrhetinic acid results in decreased activity of HSD11B2 protein Glycyrrhetinic Acid inhibits the reaction [tributyltin results in increased activity of HSD11B2 protein]; Glycyrrhetinic Acid inhibits the reaction [triphenyltin chloride results in increased activity of HSD11B2 protein] |
CTD |
PMID:24135201 PMID:31927052 |
|
NCBI chr19:33,397,656...33,402,899
Ensembl chr19:33,397,656...33,402,899
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
multiple interactions |
ISO |
[Glycyrrhetinic Acid co-treated with NADP] binds to HSD3B1 protein |
CTD |
PMID:25526675 |
|
NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
EXP |
18alpha-glycyrrhetinic acid inhibits the reaction [bisphenol A results in increased expression of HSPA5 mRNA] |
CTD |
PMID:35699857 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO EXP |
Glycyrrhetinic Acid promotes the reaction [Hydrocortisone inhibits the reaction [IL1B protein results in increased secretion of CSF2 protein]] Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B mRNA] 18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in increased expression of IL1B protein] |
CTD |
PMID:10460758 PMID:23373965 PMID:28414158 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL6 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL6 mRNA] |
CTD |
PMID:21644799 PMID:23373965 PMID:24849676 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Irak1 |
interleukin-1 receptor-associated kinase 1 |
multiple interactions |
ISO |
Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] promotes the reaction [TRAF6 protein binds to IRAK1 protein]] |
CTD |
PMID:28213090 |
|
NCBI chr X:151,768,621...151,778,521
Ensembl chr X:151,768,777...151,778,521
|
|
G |
Irak3 |
interleukin-1 receptor-associated kinase 3 |
multiple interactions increases expression |
ISO |
[Glycyrrhetinic Acid co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of IRAK3 mRNA; IRAK3 protein promotes the reaction [Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TNF protein]] Glycyrrhetinic Acid results in increased expression of IRAK3 protein |
CTD |
PMID:28213090 |
|
NCBI chr 7:55,653,949...55,714,371
Ensembl chr 7:55,653,962...55,713,121
|
|
G |
Ly96 |
lymphocyte antigen 96 |
multiple interactions |
ISO |
Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of [TLR4 protein binds to LY96 protein]] |
CTD |
PMID:28213090 |
|
NCBI chr 5:2,582,233...2,612,357
Ensembl chr 5:2,582,254...2,612,386
|
|
G |
Map3k5 |
mitogen-activated protein kinase kinase kinase 5 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [Cadmium Chloride results in increased expression of MAP3K5 protein] |
CTD |
PMID:29444456 |
|
NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:23373965 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:23373965 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased activity of MMP9 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA] |
CTD |
PMID:24613819 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
Glycyrrhetinic Acid inhibits the reaction [diosbulbin B results in increased activity of MPO protein] |
CTD |
PMID:36807597 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of MTTP mRNA] |
CTD |
PMID:28549656 |
|
NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions increases expression |
ISO EXP |
[Glycyrrhetinic Acid results in increased expression of NFE2L2] which results in decreased susceptibility to Carbon Tetrachloride; Glycyrrhetinic Acid inhibits the reaction [Carbon Tetrachloride affects the localization of NFE2L2 protein] 18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in decreased expression of NFE2L2 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in decreased expression of NFE2L2 protein] |
CTD |
PMID:23341968 PMID:28414158 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in decreased expression of NFKB1 protein] |
CTD |
PMID:24613819 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased phosphorylation of and results in increased degradation of NFKBIA protein] Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased phosphorylation of NFKBIA protein]; Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of and affects the localization of NFKBIA protein] |
CTD |
PMID:23373965 PMID:24613819 PMID:28213090 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 protein]; Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 protein] |
CTD |
PMID:21644799 PMID:23373965 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Npc1l1 |
NPC1 like intracellular cholesterol transporter 1 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of NPC1L1 mRNA] |
CTD |
PMID:28549656 |
|
NCBI chr14:81,071,448...81,091,113
Ensembl chr14:81,071,451...81,091,113
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
EXP |
glycyrrhetinic acid inhibits the reaction [1-naphthyl isothiocyanate decreases expression of Nr1h4 mRNA in liver] |
RGD |
PMID:30061734 |
RGD:15092071 |
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in decreased expression of BAX protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in decreased expression of CDKN1B protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of BCL2 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of RHOA mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of RHOA protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of ROCK1 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of ROCK1 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of ROCK2 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of ROCK2 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased phosphorylation of PPP1R12A protein] |
CTD |
PMID:31325423 |
|
NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984
|
|
G |
Pik3cd |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta |
decreases activity |
ISO |
18alpha-glycyrrhetinic acid results in decreased activity of PIK3CD protein |
CTD |
PMID:21644799 |
|
NCBI chr 5:160,094,952...160,142,962
Ensembl chr 5:160,094,952...160,120,930
|
|
G |
Pik3cg |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma |
decreases activity |
ISO |
18alpha-glycyrrhetinic acid results in decreased activity of PIK3CG protein |
CTD |
PMID:21644799 |
|
NCBI chr 6:48,766,778...48,802,098
Ensembl chr 6:48,766,864...48,802,043
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
EXP |
18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in decreased expression of PPARG mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in decreased expression of PPARG protein] |
CTD |
PMID:28414158 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppp1r12a |
protein phosphatase 1, regulatory subunit 12A |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased phosphorylation of PPP1R12A protein] |
CTD |
PMID:31325423 |
|
NCBI chr 7:43,482,808...43,593,689
Ensembl chr 7:43,482,803...43,593,425
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 protein] |
CTD |
PMID:21644799 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in decreased expression of RELA protein] Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of RELA protein] |
CTD |
PMID:23373965 PMID:24613819 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Ren |
renin |
decreases activity |
ISO |
Glycyrrhetinic Acid results in decreased activity of REN protein |
CTD |
PMID:20460744 |
|
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
|
|
G |
Rhoa |
ras homolog family member A |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of RHOA mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of RHOA protein] |
CTD |
PMID:31325423 |
|
NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746
|
|
G |
Rock1 |
Rho-associated coiled-coil containing protein kinase 1 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of ROCK1 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of ROCK1 protein] |
CTD |
PMID:31325423 |
|
NCBI chr18:1,114,532...1,236,345
Ensembl chr18:1,115,905...1,235,571
|
|
G |
Rock2 |
Rho-associated coiled-coil containing protein kinase 2 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of ROCK2 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [[PDGFB protein co-treated with PDGFB protein] results in increased expression of ROCK2 protein] |
CTD |
PMID:31325423 |
|
NCBI chr 6:39,679,116...39,774,033
Ensembl chr 6:39,679,082...39,774,031
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased activity of RUNX2 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [RUNX2 protein results in increased expression of ALPL mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [RUNX2 protein results in increased expression of BGLAP mRNA] |
CTD |
PMID:21910061 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Slc51b |
SLC51 subunit beta |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of SLC51B mRNA] |
CTD |
PMID:28549656 |
|
NCBI chr 8:65,931,891...65,939,953
Ensembl chr 8:65,931,890...65,940,145
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of SLCO1A4 mRNA] |
CTD |
PMID:28549656 |
|
NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573
|
|
G |
Sod3 |
superoxide dismutase 3 |
multiple interactions |
ISO |
Glycyrrhetinic Acid inhibits the reaction [Carbon Tetrachloride results in decreased expression of SOD3 mRNA] |
CTD |
PMID:23341968 |
|
NCBI chr14:58,610,104...58,615,845
Ensembl chr14:58,609,958...58,615,990
|
|
G |
Sp7 |
Sp7 transcription factor |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [BMP2 protein results in increased expression of SP7 mRNA] |
CTD |
PMID:21910061 |
|
NCBI chr 7:133,484,609...133,494,788
Ensembl chr 7:133,484,609...133,494,847
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
ISO |
Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of [TLR4 protein binds to LY96 protein]] |
CTD |
PMID:28213090 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO EXP |
18alpha-glycyrrhetinic acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TNF protein]; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of and results in increased secretion of TNF protein]; Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] results in increased expression of TNF mRNA]; Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TNF protein]; IRAK3 protein promotes the reaction [Glycyrrhetinic Acid inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TNF protein]] 18alpha-glycyrrhetinic acid inhibits the reaction [Methotrexate results in increased expression of TNF protein] 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in decreased expression of NFKB1 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in decreased expression of RELA protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased activity of MMP9 protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of VEGFA protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased expression of VEGFA mRNA]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased phosphorylation of and results in increased degradation of NFKBIA protein] |
CTD |
PMID:21644799 PMID:24613819 PMID:28213090 PMID:28414158 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Traf6 |
TNF receptor associated factor 6 |
multiple interactions |
ISO |
Glycyrrhetinic Acid inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Galactosamine] promotes the reaction [TRAF6 protein binds to IRAK1 protein]] |
CTD |
PMID:28213090 |
|
NCBI chr 3:87,963,517...87,988,316
Ensembl chr 3:87,963,514...87,983,507
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of VEGFA protein]; 18alpha-glycyrrhetinic acid inhibits the reaction [TNF protein results in increased expression of VEGFA mRNA] |
CTD |
PMID:24613819 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Xbp1 |
X-box binding protein 1 |
multiple interactions |
ISO |
18alpha-glycyrrhetinic acid inhibits the reaction [Cadmium Chloride results in increased expression of XBP1 protein alternative form] |
CTD |
PMID:29444456 |
|
NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression multiple interactions |
ISO |
hyperforin results in increased expression of ABCB1; hyperforin results in increased expression of ABCB1 mRNA hyperforin inhibits the reaction [ABCB1 protein results in increased secretion of Ritonavir] |
CTD |
PMID:15266218 PMID:16005588 PMID:24259679 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Alas1 |
5'-aminolevulinate synthase 1 |
increases expression |
ISO |
hyperforin results in increased expression of ALAS1 mRNA |
CTD |
PMID:24259679 |
|
NCBI chr 8:106,876,514...106,889,917
Ensembl chr 8:106,876,514...106,889,917
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
increases expression |
ISO |
hyperforin results in increased expression of BAK1 protein |
CTD |
PMID:32485087 |
|
NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
decreases expression multiple interactions increases expression |
EXP ISO |
hyperforin results in decreased expression of BAX mRNA hyperforin inhibits the reaction [aluminum maltolate results in increased expression of BAX mRNA] hyperforin results in increased expression of BAX protein |
CTD |
PMID:30481499 PMID:32485087 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions increases expression |
ISO EXP |
hyperforin inhibits the reaction [aluminum maltolate results in decreased expression of BCL2 mRNA] hyperforin results in increased expression of BCL2 mRNA |
CTD |
PMID:30481499 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage decreases expression |
ISO EXP |
hyperforin inhibits the reaction [aluminum maltolate results in increased activity of CASP3 protein]; hyperforin inhibits the reaction [aluminum maltolate results in increased expression of CASP3 mRNA] hyperforin results in increased cleavage of CASP3 protein hyperforin results in decreased expression of CASP3 mRNA hyperforin inhibits the reaction [aluminum maltolate results in increased activity of CASP3 protein]; hyperforin inhibits the reaction [aluminum maltolate results in increased expression of CASP3 mRNA]; hyperforin inhibits the reaction [Propofol results in increased cleavage of CASP3 protein] |
CTD |
PMID:30481499 PMID:32485087 PMID:36640868 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
increases cleavage |
ISO |
hyperforin results in increased cleavage of CASP8 protein |
CTD |
PMID:32485087 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
hyperforin results in decreased expression of CCND1 protein |
CTD |
PMID:32485087 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
decreases expression |
ISO |
hyperforin results in decreased expression of CFLAR protein |
CTD |
PMID:32485087 |
|
NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions decreases expression |
EXP ISO |
hyperforin inhibits the reaction [aluminum maltolate results in increased expression of CYCS protein] hyperforin results in decreased expression of CYCS protein |
CTD |
PMID:30481499 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions decreases activity |
ISO |
hyperforin inhibits the reaction [CYP1A1 protein affects the metabolism of benzo(a)pyrene 7,8-dihydrodiol] hyperforin results in decreased activity of CYP1A1 protein |
CTD |
PMID:14633740 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp24a1 |
cytochrome P450, family 24, subfamily a, polypeptide 1 |
increases expression |
ISO |
hyperforin results in increased expression of CYP24A1 mRNA |
CTD |
PMID:15630458 |
|
NCBI chr 3:159,275,947...159,290,383
Ensembl chr 3:159,275,947...159,290,383
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
increases expression |
ISO |
hyperforin results in increased expression of CYP2B6 mRNA |
CTD |
PMID:24259679 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
increases expression multiple interactions |
ISO |
hyperforin results in increased expression of CYP2C9 mRNA hyperforin results in increased expression of and results in increased activity of CYP2C9 protein; NR1I2 protein affects the reaction [hyperforin results in increased expression of CYP2C9 mRNA] |
CTD |
PMID:14600250 PMID:15100173 PMID:24259679 |
|
NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases expression multiple interactions decreases activity |
ISO |
hyperforin results in increased expression of CYP3A4; hyperforin results in increased expression of CYP3A4 mRNA hyperforin results in increased expression of and results in increased activity of CYP3A4 protein hyperforin results in decreased activity of CYP3A4 protein |
CTD |
PMID:15100173 PMID:15266218 PMID:16005588 PMID:16442130 PMID:17954527 PMID:24259679 More...
|
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
increases expression |
ISO |
hyperforin results in increased expression of CYP3A5 mRNA |
CTD |
PMID:24259679 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
decreases expression |
ISO |
hyperforin results in decreased expression of CYP7A1 mRNA |
CTD |
PMID:24259679 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Egfr |
epidermal growth factor receptor |
decreases phosphorylation |
ISO |
hyperforin results in decreased phosphorylation of EGFR protein |
CTD |
PMID:32485087 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression |
ISO |
hyperforin results in increased expression of FAS protein |
CTD |
PMID:32485087 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
increases expression |
ISO |
hyperforin results in increased expression of FASLG protein |
CTD |
PMID:32485087 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
increases expression |
ISO |
hyperforin results in increased expression of ICAM1 mRNA |
CTD |
PMID:15622447 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
hyperforin promotes the reaction [JUN protein binds to CXCL8 promoter] |
CTD |
PMID:15622447 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation decreases phosphorylation |
ISO |
hyperforin results in increased phosphorylation of MAPK1 protein hyperforin results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:15622447 PMID:32485087 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation decreases phosphorylation |
ISO |
hyperforin results in increased phosphorylation of MAPK3 protein hyperforin results in decreased phosphorylation of MAPK3 protein |
CTD |
PMID:15622447 PMID:32485087 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
decreases expression |
ISO |
hyperforin results in decreased expression of MCL1 protein |
CTD |
PMID:32485087 |
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions increases response to substance affects binding increases activity |
ISO |
[NR1I2 protein co-treated with hyperforin] results in decreased expression of SLC22A1 mRNA; [NR1I2 protein results in increased susceptibility to hyperforin] which results in decreased expression of SLC22A1 mRNA; hyperforin binds to and results in increased activity of NR1I2 protein; hyperforin promotes the reaction [NR1I2 protein results in decreased expression of SLC22A1 mRNA]; NR1I2 protein affects the reaction [hyperforin results in increased expression of CYP2C9 mRNA]; NR1I2 protein promotes the reaction [hyperforin results in increased abundance of Lipids] hyperforin binds to NR1I2 protein hyperforin results in increased activity of NR1I2 protein |
CTD |
PMID:14600250 PMID:15630458 PMID:15856409 PMID:20079722 PMID:26187274 PMID:26920453 PMID:27071811 More...
|
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Por |
cytochrome p450 oxidoreductase |
increases expression |
ISO |
hyperforin results in increased expression of POR mRNA |
CTD |
PMID:24259679 |
|
NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245
|
|
G |
Slc22a1 |
solute carrier family 22 member 1 |
decreases expression multiple interactions |
ISO |
hyperforin results in decreased expression of SLC22A1 protein [NR1I2 protein co-treated with hyperforin] results in decreased expression of SLC22A1 mRNA; [NR1I2 protein results in increased susceptibility to hyperforin] which results in decreased expression of SLC22A1 mRNA; hyperforin promotes the reaction [NR1I2 protein results in decreased expression of SLC22A1 mRNA] |
CTD |
PMID:26920453 |
|
NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678
|
|
G |
Trpc6 |
transient receptor potential cation channel, subfamily C, member 6 |
multiple interactions |
EXP |
hyperforin inhibits the reaction [Propofol results in decreased expression of TRPC6 protein] |
CTD |
PMID:36640868 |
|
NCBI chr 8:5,759,387...5,864,000
Ensembl chr 8:5,758,935...5,828,092
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
increases expression |
ISO |
hyperforin results in increased expression of UGT1A1 mRNA |
CTD |
PMID:24259679 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
decreases expression |
ISO |
hyperforin results in decreased expression of XIAP protein |
CTD |
PMID:32485087 |
|
NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700
|
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
lucidenic acid N analog results in increased expression of HMOX1 protein |
CTD |
PMID:25239868 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO |
omaveloxolone analog inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in decreased expression of ADIPOQ protein] |
CTD |
PMID:32410268 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Fth1 |
ferritin heavy chain 1 |
multiple interactions |
ISO |
omaveloxolone analog promotes the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of FTH1 mRNA]; omaveloxolone promotes the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of FTH1 mRNA] |
CTD |
PMID:32410268 |
|
NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
[omaveloxolone analog co-treated with Streptozocin co-treated with Dietary Fats] results in increased expression of GPT protein |
CTD |
PMID:32410268 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Lep |
leptin |
multiple interactions |
ISO |
omaveloxolone analog promotes the reaction [[Streptozocin co-treated with Dietary Fats] results in decreased expression of LEP protein] |
CTD |
PMID:32410268 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
[omaveloxolone analog co-treated with Streptozocin co-treated with Dietary Fats] results in increased activity of NQO1 protein; [omaveloxolone co-treated with Streptozocin co-treated with Dietary Fats] results in increased activity of NQO1 protein; omaveloxolone analog promotes the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of NQO1 mRNA]; omaveloxolone promotes the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of NQO1 mRNA] |
CTD |
PMID:32410268 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Srxn1 |
sulfiredoxin 1 |
multiple interactions |
ISO |
omaveloxolone analog promotes the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of SRXN1 mRNA]; omaveloxolone promotes the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of SRXN1 mRNA] |
CTD |
PMID:32410268 |
|
NCBI chr 3:140,604,490...140,610,050
Ensembl chr 3:140,599,608...140,628,448
|
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
affects activity |
ISO |
rubiarbonone C affects the activity of CYP3A4 protein |
CTD |
PMID:30259074 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp4f18 |
cytochrome P450, family 4, subfamily f, polypeptide 18 |
decreases activity multiple interactions |
ISO |
rubiarbonone C results in decreased activity of CYP4F3 protein alternative form rubiarbonone C inhibits the reaction [CYP4F3 protein alternative form results in increased hydroxylation of Arachidonic Acid] |
CTD |
PMID:30259074 |
|
NCBI chr16:17,763,543...17,804,944
Ensembl chr16:17,707,317...17,804,940
|
|